Cel Sci (CVM) Capital Expenditures Growth (5y) (2015 - 2025)
Cel Sci (CVM) Capital Expenditures Growth (5y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -65.94% |
| Dec 31, 2024 | -20.20% |
| Sep 30, 2024 | 38.30% |
| Jun 30, 2024 | 15.67% |
| Dec 31, 2023 | 53.14% |
| Jun 30, 2023 | 26.20% |
| Mar 31, 2022 | 170.12% |
| Dec 31, 2021 | 20.12% |
| Sep 30, 2021 | 73.58% |
| Jun 30, 2021 | 1,007.52% |
| Mar 31, 2021 | 237.20% |
| Dec 31, 2020 | 192.03% |
| Sep 30, 2020 | 131.86% |
| Mar 31, 2017 | -23.69% |
| Dec 31, 2016 | -16.18% |
| Sep 30, 2016 | -10.04% |
| Jun 30, 2016 | -14.87% |
| Mar 31, 2016 | -16.18% |
| Dec 31, 2015 | -11.77% |
| Sep 30, 2015 | -54.51% |